Blar i St. Olavs hospital på forfatter "Ystrøm, Carl Magnus"

Viser treff 1-5 av 5

    • Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial 

      Syversen, Silje Watterdal; Goll, Guro Løvik; Jørgensen, Kristin Kaasen; Sandanger, Øystein; Sexton, Joseph; Olsen, Inge Christoffer; Gehin, Johanna Elin; Warren, David; Brun, Marthe Kirkesæther; Klaasen, Rolf; Karlsen, Lars Normann; Noraberg, Geir; Zettel, Camilla; Ljoså, Maud-Kristine Aga; Haugen, Anne Julsrud; Njålla, Rune Johan; Bruun, Trude J; Seeberg, Kathrine; Michelsen, Brigitte; Strand, Eldri Kveine; Skorpe, Svanaug; Blomgren, Ingrid; Bragnes, Yngvill; Dotterud, Christian; Thune, Turid Jorunn; Ystrøm, Carl Magnus; Torp, Roald; Pawel, Mielnik; Mørk, Cato; Kvien, Tore Kristian; Jahnsen, Jørgen; Bolstad, Nils; Haavardsholm, Espen A. (Peer reviewed; Journal article, 2021)
      Importance: Proactive therapeutic drug monitoring (TDM), defined as individualized drug dosing based on scheduled monitoring of serum drug levels, has been proposed as an alternative to standard therapy to maximize efficacy ...

    • Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials 

      Jørgensen, Kristin Kaasen; Goll, Guro Løvik; Sexton, Joe; Bolstad, Nils; Olsen, Inge C.; Asak, Øivind Wessel; Berset, Ingrid Prytz; Blomgren, Ingrid; Dvergsnes, Katrine; Florholmen, Jon; Frigstad, Svein Oskar; Henriksen, Magne; Hagfors, Jon; Huppertz-Hauss, Gert; Haavardsholm, Espen Andre; Klaasen, Rolf Anton; Moum, Bjørn; Noraberg, Geir; Prestegård, Ulf; Rydning, Jan Henrik; Sagatun, Liv; Seeberg, Kathrine; Torp, Roald; Vold, Cecilia; Warren, David J.; Ystrøm, Carl Magnus; Lundin, Knut Erik Aslaksen; Kvien, Tore Kristian; Jahnsen, Jørgen (Peer reviewed; Journal article, 2020)
      Background - The NOR-SWITCH main and extension trials demonstrated that switching from originator to biosimilar infliximab (CT-P13) is efficacious and safe across six diseases. However, a subgroup analysis of Crohn’s disease ...

    • Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 : A Randomized Trial 

      Barratt-Due, Andreas; Olsen, Inge Christoffer; Nezvalova-Henriksen, Katerina; Kåsine, Trine; Lund-Johansen, Fridtjof; Hoel, Hedda Benedicte; Holten, Aleksander Rygh; Tveita, Anders Aune; Mathiessen, Alexander; Haugli, Mette; Eiken, Ragnhild; Kildal, Anders Benjamin; Berg, Åse; Johannessen, Asgeir; Heggelund, Lars; Dahl, Tuva Børresdatter; Skåra, Karoline Hansen; Pawel, Mielnik; Le, Lan Ai Kieu; Thoresen, Lars; Ernst, Gernot; Hoff, Dag Arne Lihaug; Skudal, Hilde Kristin; Kittang, Bård Reiakvam; Olsen, Roy Bjørkholt; Tholin, Birgitte; Ystrøm, Carl Magnus; Skei, Nina Vibeche; Tran, Trung; Dudman, Susanne Gjeruldsen; Andersen, Jan Terje; Hannula, Raisa; Dalgard, Olav; Finbråten, Ane-Kristine; Tonby, Kristian; Blomberg, Bjørn; Aballi, Saad; Fladeby, Cathrine; Steffensen, Anne Katrine; Müller, Fredrik; Dyrhol-Riise, Anne Ma; Trøseid, Marius; Aukrust, Pål (Peer reviewed; Journal article, 2021)
      Background: New treatment modalities are urgently needed for patients with COVID-19. The World Health Organization (WHO) Solidarity trial showed no effect of remdesivir or hydroxychloroquine (HCQ) on mortality, but the ...

    • Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: Open‐label extension of the NOR‐SWITCH trial 

      Goll, Guro Løvik; Jørgensen, Kristin Kaasen; Sexton, Joseph; Olsen, Inge Christoffer; Bolstad, Nils; Haavardsholm, Espen A.; Lundin, Knut Erik Aslaksen; Tveit, Kåre Steinar; Lorentzen, Merete; Berset, Ingrid Prytz; Fevang, Bjørg-Tilde Svanes; Kalstad, Synnøve; Ryggen, Kristin; Warren, David; Klaasen, Rolf; Asak, Øivind Wessel; Baigh, Somyeh; Blomgren, Ingrid; Brenna, Øystein; Bruun, Trude J; Dvergsnes, Katrine; Frigstad, Svein Oskar; Myrnes, Inger; Hatten, Ingvild Helgheim; Huppertz-Hauss, Gert; Henriksen, Magne; Hoie, Sunniva S.; Krogh, Jan Reidar; Midtgard, Irina P.; Mielnik, Pawel; Moum, Bjørn; Noraberg, Geir; Poyan, Armin; Prestegård, Ulf; Rashid, Haroon Ur; Strand, Eldri Kveine; Skjetne, Kristine; Seeberg, Kathrine; Torp, Roald; Ystrøm, Carl Magnus; Vold, Cecilia; Zettel, Camilla C.; Waksvik, Kenneth; Gulbrandsen, Bjørn; Hagfors, Jon; Mørk, Cato; Jahnsen, Jørgen; Kvien, Tore Kristian (Journal article; Peer reviewed, 2019)
      Background and objectives The 52‐week, randomized, double‐blind, noninferiority, government‐funded NOR‐SWITCH trial demonstrated that switching from infliximab originator to less expensive biosimilar CT‐P13 was not ...

    • Respiratory dysfunction three months after severe COVID-19 is associated with gut microbiota alterations 

      Vestad, Beate; Ueland, Thor; Lerum, Tøri Vigeland; Dahl, Tuva Børresdatter; Holm, Kristian; Barratt-Due, Andreas; Kåsine, Trine; Dyrhol-Riise, Anne Ma; Stiksrud, Birgitte; Tonby, Kristian; Hoel, Hedda; Olsen, Inge Christoffer; Henriksen, Katerina N.; Tveita, Anders Aune; Manotheepan, Ravinea; Haugli, Mette; Eiken, Ragnhild; Berg, Åse; Halvorsen, Bente; Lekva, Tove; Ranheim, Trine; Michelsen, Annika Elisabeth; Kildal, Anders Benjamin; Johannessen, Asgeir; Thoresen, Lars; Skudal, Hilde Kristin; Kittang, Bård Reiakvam; Olsen, Roy Bjørkholt; Ystrøm, Carl Magnus; Skei, Nina Vibeche; Hannula, Raisa; Aballi, Saad; Kvåle, Reidar; Skjønsberg, Ole Henning; Aukrust, Pål; Hov, Johannes Espolin Roksund; Trøseid, Marius (Peer reviewed; Journal article, 2022)
      Background - Although coronavirus disease 2019 (COVID-19) is primarily a respiratory infection, mounting evidence suggests that the gastrointestinal tract is involved in the disease, with gut barrier dysfunction and gut ...